On Friday, Maxim Integrated Products Inc. (NASDAQ:MXIM)’s shares inclined 0.65% to $34.02.
Imagine trying to navigate in a world drawn by Picasso. A new video from Maxim Integrated Products, Inc. (MXIM) explains how surround view systems take inputs from multiple fisheye cameras to give a complete landscape view around an automobile.
The video, “Surround View: From Fisheye to Birdseye,” illustrates how the MAX9286 eliminates components, shortens design time, and lowers cost for automotive applications. Now, designers can easily synchronize camera inputs for an accurate birdesye view of the world’s surroundings. Just one MAX9286 gigabit multimedia serial link (GMSL) deserializer receives and automatically synchronizes video from up to four cameras.
Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs. It primarily serves automotive, communications and data center, computing, consumer, and industrial markets.
Adobe Systems Incorporated (NASDAQ:ADBE)’s shares gained 0.62% to $79.19.
Adobe (ADBE) declared it will webcast its third quarter fiscal year 2015 earnings conference call to be held next week.
What: Adobe Third Quarter Fiscal Year 2015 Earnings Conference Call
When: 2:00 p.m. Pacific Time, Thurs., Sept. 17, 2015
Where: www.adobe.com/ADBE
Adobe Systems Incorporated is a diversified software company worldwide. It operates in three segments: Digital Media, Digital Marketing, and Print and Publishing. The Digital Media segment provides tools and solutions that enable individuals, small and medium businesses, and enterprises to create, publish, promote, and monetize their digital content. This segment’s flagship product is Creative Cloud, a subscription service that allows customers to download and install the latest versions of its creative products.
At the end of Friday’s trade, Republic Airways Holdings Inc. (NASDAQ:RJET)‘s shares surged 4.29% to $3.40.
Republic Airways Holdings Inc. (RJET) stated preliminary passenger traffic results for August 2015.
The Company generated nearly 974 million revenue passenger miles (RPMs) in August, down about 6 percent contrast to the same period in 2014, with a 7 percent reduction in accessible seat miles (ASMs). Block hours declined 8 percent to about 62,000, and the load factor raised 1 percentage point contrast to the same period last year. Republic Airways carried more than 2 million passengers during the month, a decrease of 2 percent contrast to August 2014.
Republic Airways Holdings Inc., based in Indianapolis, Indiana, is an airline holding company that owns Republic Airlines and Shuttle America, collectively called “the airlines.” As of Sept. 11, 2015, the airlines operate a combined fleet of about 240 aircraft and offer planned passenger service with about 1,275 flights daily to about 110 cities in the U.S., Canada and the Caribbean through fixed-fee flights operated under our major airline partner brands of American Eagle, Delta Connection, United Express and US Airways Express.
Republic Airways Holdings Inc., through its auxiliaries, provides planned passenger services. The company offers planned passenger service on about 1,229 flights daily to about 101 cities in the U.S. and Canada. It provides fixed-fee regional airline services under United Express, Delta Connection, or US Airways Express/American Eagle. As of December 31, 2014, the company operated a combined fleet of about 244 aircraft. The company was founded in 1996 and is headquartered in Indianapolis, Indiana.
Amicus Therapeutics, Inc. (NASDAQ:FOLD), ended its Friday’s trading session with 1.17% gain, and closed at $18.16.
Amicus Therapeutics (FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, and Scioderm, Inc. a privately-held biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, have signed a definitive agreement under which Amicus will acquire 100% of the capital stock of Scioderm, Inc.
Transaction highlights
- Excellent planned fit with Amicus’ patient-centric vision to develop and commercialize advanced therapies for devastating rare and orphan diseases.
- Leverages Scioderm development team’s EB expertise with Amicus’ global clinical infrastructure to advance Zorblisa toward regulatory approvals and Amicus’ commercial, patient advocacy and medical affairs infrastructure to support a successful global launch.
- Potential first-to-market therapy to address estimated $1 billion+ global commercial opportunity.
Amicus Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapeutic products for rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
